topic

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma
Brian I. Rini, David F. McDermott, Hans Hammers, William Bro, Ronald M. Bukowski, Bernard Faba, Jo Faba, Robert A. Figlin, Thomas Hutson, Eric Jonasch, Richard W. Joseph, Bradley C. Leibovich, Thomas Olencki, Allan J. Pantuck, David I. Quinn, Virginia Seery, Martin H. Voss, Christopher G. Wood, Laura S. Wood, Michael B. Atkins

Journal for ImmunoTherapy of Cancer Dec 2016, 4 (1) 81; DOI: 10.1186/s40425-016-0180-7
Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide
Ioannis F. Voutsas, Eleftheria A. Anastasopoulou, Panagiotis Tzonis, Michael Papamichail, Sonia A. Perez, Constantin N. Baxevanis

Journal for ImmunoTherapy of Cancer Dec 2016, 4 (1) 75; DOI: 10.1186/s40425-016-0183-4
TCR diversity – a universal cancer immunotherapy biomarker?
Douglas G. McNeel

Journal for ImmunoTherapy of Cancer Dec 2016, 4 (1) 69; DOI: 10.1186/s40425-016-0175-4
Validation of biomarkers to predict response to immunotherapy in cancer: Volume II — clinical validation and regulatory considerations
Kevin K. Dobbin, Alessandra Cesano, John Alvarez, Rachael Hawtin, Sylvia Janetzki, Ilan Kirsch, Giuseppe V. Masucci, Paul B. Robbins, Senthamil R. Selvan, Howard Z. Streicher, Jenny Zhang, Lisa H. Butterfield, Magdalena Thurin

Journal for ImmunoTherapy of Cancer Dec 2016, 4 (1) 77; DOI: 10.1186/s40425-016-0179-0
Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy
Shruti Agrawal, Yan Feng, Amit Roy, Georgia Kollia, Brian Lestini

Journal for ImmunoTherapy of Cancer Dec 2016, 4 (1) 72; DOI: 10.1186/s40425-016-0177-2
Validation of biomarkers to predict response to immunotherapy in cancer: Volume I — pre-analytical and analytical validation
Giuseppe V. Masucci, Alessandra Cesano, Rachael Hawtin, Sylvia Janetzki, Jenny Zhang, Ilan Kirsch, Kevin K. Dobbin, John Alvarez, Paul B. Robbins, Senthamil R. Selvan, Howard Z. Streicher, Lisa H. Butterfield, Magdalena Thurin

Journal for ImmunoTherapy of Cancer Dec 2016, 4 (1) 76; DOI: 10.1186/s40425-016-0178-1
Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810
Gerald S. Falchook, Rom Leidner, Elizabeth Stankevich, Brian Piening, Carlo Bifulco, Israel Lowy, Matthew G. Fury

Journal for ImmunoTherapy of Cancer Dec 2016, 4 (1) 70; DOI: 10.1186/s40425-016-0176-3
Application of the Immunoscore as prognostic tool for hepatocellular carcinoma
Annacarmen Petrizzo, Luigi Buonaguro

Journal for ImmunoTherapy of Cancer Dec 2016, 4 (1) 71; DOI: 10.1186/s40425-016-0182-5
Classical and non-classical HLA class I aberrations in primary cervical squamous- and adenocarcinomas and paired lymph node metastases
Debbie M. Ferns, A. Marijne Heeren, Sanne Samuels, Maaike C. G. Bleeker, Tanja D. de Gruijl, Gemma G. Kenter, Ekaterina S. Jordanova

Journal for ImmunoTherapy of Cancer Dec 2016, 4 (1) 78; DOI: 10.1186/s40425-016-0184-3
PD1/PD-L1 inhibition as a potential radiosensitizer in head and neck squamous cell carcinoma: a case report
Misako Nagasaka, Mark Zaki, Harold Kim, S. Naweed Raza, George Yoo, Ho-sheng Lin, Ammar Sukari

Journal for ImmunoTherapy of Cancer Dec 2016, 4 (1) 83; DOI: 10.1186/s40425-016-0187-0

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages